Jaguar Health, Inc. (JAGX)
| Market Cap | 5.40M +68.4% |
| Revenue (ttm) | 11.51M -1.5% |
| Net Income | -53.58M |
| EPS | -22.97 |
| Shares Out | 13.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 739,003 |
| Open | 0.4200 |
| Previous Close | 0.4286 |
| Day's Range | 0.4041 - 0.4447 |
| 52-Week Range | 0.3130 - 15.4800 |
| Beta | 0.29 |
| Analysts | Strong Buy |
| Price Target | 60.00 (+14,354.35%) |
| Earnings Date | Apr 7, 2026 |
About JAGX
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiret... [Read more]
Financial Performance
In 2025, Jaguar Health's revenue was $11.51 million, a decrease of -1.52% compared to the previous year's $11.69 million. Losses were -$53.58 million, 39.2% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for JAGX stock is "Strong Buy" and the 12-month stock price target is $60.0.
News
Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs
Global Market for Short Bowel Syndrome, Including Intestinal Failure (IF), Estimated to Reach $8.0 Billion by 20331 AI data mining of real world clinical and symptom manifestation is beneficial in the...
Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
Click here to register SAN FRANCISCO, CA / ACCESS Newswire / April 9, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) Participation Instructions for Webcast When: Friday, April 10, 2026 at 8:30 a.m. Eastern ...
Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Topline results expected within a month and may complement positive results of a study of crofelemer for treatment of cancer therapy-induced diarrhea (CTD) in dogs receiving neratinib - a targeted tyr...
Jaguar Health Reports 2025 Financials
Net revenue increase of 5% in Q4 2025 vs. Q3 2025 Jaguar received an up-front payment of $16Mof non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® an...
Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Jaguar continues its sharp strategic focus on its global development program for crofelemer for rare-disease intestinal failure (IF) indications; all patients with microvillus inclusion disease (MVID)...
FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
MVID has a lethal natural history requiring life-sustaining parenteral support (PS), which includes total parenteral nutrition (TPN), which is associated with significant toxicities; PS reduction coul...
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression
Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management SAN FRANCISCO, CA / ACCESS Newswire / March 16, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("...
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts
SAN FRANCISCO, CA / ACCESS Newswire / March 11, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, ...
Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants
Strengthening balance sheet and capitalization is a key Jaguar priority Company continues its sharp, strategic focus on global development program for crofelemer for rare-disease intestinal failure in...
Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1
As announced , Jaguar received an up-front payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two co...
Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend
Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / March 2, 2026 / Jaguar Health, Inc...
Jaguar Health Announces a Special One-time Stock Dividend
Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt SAN FRANCISCO, CA / ACCESS Newswire / February 18, 2026 / Jaguar Health, Inc. (N...
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi
Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi® and Canalevia®-CA1, which has the potential to provide Jaguar up to an addi...
Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts
SAN FRANCISCO, CA / ACCESS Newswire / January 14, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday...
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
$18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing conditions) Up to additional $20M in milestone and other future payments Future Pak becomes exclusive U.S...
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication
Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure Associate...
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it received notice from the U.S. Food and Drug Administration's Center...
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) - for which the company completed a meeting in Octobe...
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Conditional approval extended through December 2026 for the treatment of CID in dogs CID confirmatory effectiveness trial expected to conclude in February 2026, ahead of FDA's June deadline - 51 dogs ...
Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders
Jaguar CEO Lisa Conte presenting December 10 from 3:25pm - 3:35pm Eastern at the Emerging Growth Conference to provide updates on near-term catalysts; Click here to register Initial results of ongoing...
Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study
Jaguar's requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia® A novel non-antibiotic approach to diarrhea treatment is important because ther...
Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones
This new IP supports crofelemer's global exclusivity in rare pediatric intestinal failure coincident with published clinical data showing reductions in parenteral support requirements with crofelemer ...
In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial
Crofelemer can potentially extend lives of MVID patients - infants and children who face the lethal natural history of the disease Parenteral support reduction of up to 37% is groundbreaking; No appro...
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue
Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion di...
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates
Click here to register Company plans to file its Earnings Report on November 14, 2025 on Form 10-Q for the quarter ended September 30, 2025 SAN FRANCISCO, CA / ACCESS Newswire / November 14, 2025 / Ja...